BioMarin Pharmaceutical has struck a deal to purchase fellow biotechnology firm Amicus Therapeutics for about $4.8 billion in money.
Source link
BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion
Related Posts
Thermacell LIV 2.0 Review: Taking My Yard Back
4 years in the past, I moved again to Texas from California. After two weeks of dwelling right here, I…
Microsoft makes sales chief Althoff CEO of commercial business
President of Microsoft North America Judson Althoff speaks on stage throughout We Day at KeyArena in Seattle, Washington, on April…
Closing arguments conclude Musk v. Altman, jury deliberates next week
OpenAI CEO Sam Altman arrives on the federal courthouse, because the trial in Elon Musk’s lawsuit over OpenAI’s for-profit conversion…